



Press release

Stockholm, January 25th, 2022

AlgoDx gets late-breaking intensive care abstract accepted

AlgoDx, a medical software company that brings AI to intensive care, has announced that an abstract on clinical data of its ML-based sepsis predictor NAVOY[®] Sepsis has been accepted for a poster presentation at ISICEM, which this year will be held in Brussels on March 22-25.

The paper

The poster, titled *Early prediction of sepsis in intensive care patients using a machine learning algorithm, a randomized clinical validation trial*, will be presented at the 41st International Symposium on Intensive Care & Emergency Medicine by the lead researcher of the study Fredrik Sjövall, MD, PhD, DEAA, EDIC. Co-author is Assoc Prof Dr. Inger Persson, Director of AI & Biostatistics at AlgoDx.

The study

The aim of the randomized clinical trial EXPRESS was to validate the prognostic accuracy of NAVOY[®] Sepsis at predicting sepsis in adult intensive care patients. 304 ICU patients were monitored using NAVOY[®] Sepsis, of which 44 patients had been diagnosed with Covid-19. The study (NCT04570618) is the largest randomized clinical trial with a machine learning sepsis predictor ever conducted, and the first study that clinically validates a sepsis predictor against the Sepsis-3 criteria.

Official comments

- The clinical performance with accuracy, sensitivity, and specificity were high, and all algorithm performance metrics met the criteria for a successful primary analysis, says Inger Persson, Director of AI & Biostatistics at AlgoDx.
- The positive data are very important for AlgoDx and given that NAVOY[®] Sepsis is regulatory cleared for use in EU and US, we can now continue as planned with commercial pilots in intensive care units where there still is a large unmet medical need for early detection of sepsis, said David Becedas, CEO of AlgoDx.

Funding

The trial was backed by Sweden's Innovation Agency Vinnova through their SweLife and Medtech4Health call.

About AlgoDx and the NAVOY[®] portfolio

AlgoDx is a Swedish medical software company associated with Uppsala University. AlgoDx has developed and clinically validated NAVOY[®] Sepsis, an algorithm that accurately predicts sepsis onset in ICU patients up to three hours earlier. In addition, AlgoDx has developed NAVOY[®] Acute Kidney Injury to predict AKI up to twelve hours earlier in intensive care. Both products are regulatory cleared as clinical decision support for use in EU and US. The company also has a pipeline with three additional algorithm product candidates for intensive care based on machine learning. A common trait is that these software products only need routinely collected vital signs and ICU clinical data to make accurate predictions to serve as clinical decision support.

Press contacts: David Becedas, CEO AlgoDx. Tel: +46 72 232 83 48. david.becedas@algodx.com